


PRODUCT INFORMATION



GRI-977143

Item No. 21900

CAS Registry No.: 325850-81-5
Formal Name: 2-[[3-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)propyl]thio]-benzoic acid
MF: C₂₂H₁₇NO₄S
FW: 391.4
Purity: ≥98%
UV/Vis.: λ_{max}: 232 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GRI-977143 is supplied as a crystalline solid. A stock solution may be made by dissolving the GRI-977143 in the solvent of choice. GRI-977143 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of GRI-977143 in these solvents is approximately 10 mg/ml.

GRI-977143 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GRI-977143 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GRI-977143 has a solubility of approximately 0.025 mg/ml in a 1:40 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GRI-977143 is an agonist of G protein-coupled lysophosphatidic acid receptor 2 (LPA₂) with an EC₅₀ value of 3.3 μM in LPA₂-transfected RH7777 cells.¹ It is selective for LPA₂, having no activity at LPA₁, LPA₃, LPA₄, and LPA₅ at concentrations up to 10 μM. GRI-977143 increases growth and reduces caspase-3 and -7 activation in LPA₂-transduced MEF fibroblasts. It increases MM1 rat hepatoma cell invasion and inhibits apoptosis of IEC-6 cells induced by TNF-α, doxorubicin (Item No. 15007), or serum withdrawal. GRI-977143 also rescues apoptotic cells from γ-irradiation-induced injury *in vitro* and *in vivo*.²

References

1. Kiss, G.N., Fells, J.I., Gupte, R.D., *et al.* Virtual screening for LPA₂-specific agonists identifies a nonlipid compound with antiapoptotic actions. *Mol. Pharmacol.* **82**(6), 1162-1173 (2012).
2. Kiss, G.N., Lee, S.-C., Fells, J., *et al.* Mitigation of radiation injury by selective stimulation of the LPA₂ receptor. *Biochim. Biophys. Acta* **1831**(1), 117-125 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM